Positive Allosteric Modulators Market Size & Share, by Disease Type (Parkinson disease, Schizophrenia, Alzheimer disease); Drug Type {Galantamine, Benzodiazepines (Diazepam, Clonazepam, Lorazepam), Barbiturates (Methohexital, Phenobarbital, Secobarbital), Amantadine, Donepezil, Levodopa}; End-user (Hospital, Pharmacy) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2037

Global Market Size, Forecast, and Trend Highlights Over 2025-2037

Positive Allosteric Modulators Market size is expected to expand at significant growth rate during the forecast period i.e., between 2025-2037.

Allosteric modulators are substances that bind to a receptor to change the receptor's response to stimulus. Positive allosteric modulators function to facilitate agonist-mediated response. The growth of the market can be attributed to the increasing prevalence of mental disorders, such as, dementia, schizophrenia, and others, as positive allosteric modulators are used as a novel treatment approach for the patients. Positive allosteric modulators can be provided to the patients in combination with their currently approved anti-AD drugs, to improve the efficacy of the drugs. The growing cases of Alzheimer’s disease is anticipated to primarily drive the market growth. As per the data by the World Health Organization (WHO), 55 million people live with dementia worldwide, as of 2020, and there are nearly 10 million new cases every year. Out of these 60-70% cases are of Alzheimer’s disease. Moreover, allosteric modulators are also used for medical research and development of new drugs. As per the data by the World Bank, 9.858% of the global gross domestic product (GDP) was spent on healthcare, while research and development expenditure amounted to 2.203% of the GDP in 2018.